Literature DB >> 3944240

Angiotensin II-like immunoreactivity in human ovarian follicular fluid.

M D Culler, B C Tarlatzis, A Lightman, L A Fernandez, A H Decherney, A Negro-Vilar, F Naftolin.   

Abstract

Human ovarian follicular fluid (hFF) has angiogenic activity, although the causative factors are unknown. We recently found that hFF contains renin activity which converts renin substrate to angiotensin I (AI). Since the enzymatic cleavage product of AI, angiotensin II (AII), is a potent stimulator of new vessel formation, we have examined Sephadex G-25 column fractions of hFF and extracted hFF and plasma from individual patients for AII-like immunoreactivity (AII-IR). Eluent fractions from Sephadex G-25 column chromatography of hFF had significant AII-IR which eluted in the same fractions as synthetic AII. Individual, extracted FF samples contained approximately 10 times higher levels of AII-IR than extracts of plasma from the same patients. Serial dilutions of the Sephadex column fractions and extracted FF and plasma inhibited binding of 125I-AII to rabbit anti-AII serum in a manner parallel to the inhibition caused by synthetic AII, indicating that the detected immunoreactivity was not due to non-specific assay interference. In summary, the results indicate the presence of significant AII-like immunoreactivity in hFF. AII may now be considered as a potential mediator of the angiogenic activity present in hFF and may play an important paracrine and/or autocrine role in physiologic events in the ovary.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3944240     DOI: 10.1210/jcem-62-3-613

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Intraovarian markers of follicular and oocyte maturation.

Authors:  A Pellicer; M P Diamond; A H DeCherney; F Naftolin
Journal:  J In Vitro Fert Embryo Transf       Date:  1987-08

2.  Features of the Renin-angiotensin system in ascites and pleural effusion during severe ovarian hyperstimulation syndrome.

Authors:  A Delbaere; P J Bergmann; Y Englert
Journal:  J Assist Reprod Genet       Date:  1997-05       Impact factor: 3.412

3.  Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations.

Authors:  J Itskovitz; J E Sealey; N Glorioso; Z Rosenwaks
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  The immunocytochemical localization of angiotensinogen in the rat ovary.

Authors:  W G Thomas; C Sernia
Journal:  Cell Tissue Res       Date:  1990-08       Impact factor: 5.249

5.  Interactions between insulin-like growth factor-I (IGF-I) and the renin-angiotensin system in follicular growth and ovulation.

Authors:  Y Yoshimura; N Aoki; K Sueoka; T Miyazaki; N Kuji; M Tanaka; T Kobayashi
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

6.  Angiotensins stimulate in vitro ovulation and contraction of brook trout (Salvelinus fontinalis) follicles.

Authors:  S Y Hsu; F W Goetz
Journal:  Fish Physiol Biochem       Date:  1992-12       Impact factor: 2.794

7.  Localization of angiotensin II receptors in ovarian follicles and the identification of angiotensin II in rat ovaries.

Authors:  A Husain; F M Bumpus; P De Silva; R C Speth
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Human ovarian theca cells are a source of renin.

Authors:  Y S Do; A Sherrod; R A Lobo; R J Paulson; T Shinagawa; S W Chen; S Kjos; W A Hsueh
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

Review 9.  Renin in the female reproductive system.

Authors:  W A Hsueh
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

10.  Gonadotropin stimulates ovarian renin-angiotensin system in the rabbit.

Authors:  Y Yoshimura; N Koyama; M Karube; T Oda; M Akiba; A Yoshinaga; S Shiokawa; M Jinno; Y Nakamura
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.